BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 22151356)

  • 1. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
    Rasmussen CE; Falk T; Zois NE; Moesgaard SG; Häggström J; Pedersen HD; Ablad B; Nilsen HY; Olsen LH
    J Vet Intern Med; 2012; 26(1):76-84. PubMed ID: 22151356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of pulmonary hypertension in Cavalier King Charles spaniels compared with other breeds with myxomatous mitral valve disease.
    Sudunagunta S; Green D; Christley R; Dukes-McEwan J
    J Vet Cardiol; 2019 Jun; 23():21-31. PubMed ID: 31174726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating cytokine concentrations in dogs with different degrees of myxomatous mitral valve disease.
    Zois NE; Moesgaard SG; Kjelgaard-Hansen M; Rasmussen CE; Falk T; Fossing C; Häggström J; Pedersen HD; Olsen LH
    Vet J; 2012 Apr; 192(1):106-11. PubMed ID: 21696985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Holter monitoring in clinically healthy Cavalier King Charles Spaniels, Wire-haired Dachshunds, and Cairn Terriers.
    Rasmussen CE; Vesterholm S; Ludvigsen TP; Häggström J; Pedersen HD; Moesgaard SG; Olsen LH
    J Vet Intern Med; 2011; 25(3):460-8. PubMed ID: 21418322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Holter monitoring of small breed dogs with advanced myxomatous mitral valve disease with and without a history of syncope.
    Rasmussen CE; Falk T; Domanjko Petrič A; Schaldemose M; Zois NE; Moesgaard SG; Ablad B; Nilsen HY; Ljungvall I; Höglund K; Häggström J; Pedersen HD; Bland JM; Olsen LH
    J Vet Intern Med; 2014; 28(2):363-70. PubMed ID: 24417236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart rate variability parameters of myxomatous mitral valve disease in dogs with and without heart failure obtained using 24-hour Holter electrocardiography.
    Oliveira MS; Muzzi RA; Araújo RB; Muzzi LA; Ferreira DF; Nogueira R; Silva EF
    Vet Rec; 2012 Jun; 170(24):622. PubMed ID: 22645158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.
    Cremer SE; Singletary GE; Olsen LH; Wallace K; Häggström J; Ljungvall I; Höglund K; Reynolds CA; Pizzinat N; Oyama MA
    J Vet Intern Med; 2014; 28(5):1534-40. PubMed ID: 25146933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of physical examination, electrocardiography, radiography, and biomarkers to predict echocardiographic stage B2 myxomatous mitral valve disease in preclinical Cavalier King Charles Spaniels.
    Wesselowski S; Gordon SG; Fries R; Saunders AB; Sykes KT; Vitt J; Boutet B; Häggström J; Kadotani S; Stack J; Barnett BG
    J Vet Cardiol; 2023 Dec; 50():1-16. PubMed ID: 37913604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flow-mediated vasodilation measurements in Cavalier King Charles Spaniels with increasing severity of myxomatous mitral valve disease.
    Moesgaard SG; Klostergaard C; Zois NE; Teerlink T; Molin M; Falk T; Rasmussen CE; Luis Fuentes V; Jones ID; Olsen LH
    J Vet Intern Med; 2012; 26(1):61-8. PubMed ID: 22151409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.
    Reimann MJ; Häggström J; Møller JE; Lykkesfeldt J; Falk T; Olsen LH
    J Vet Intern Med; 2017 Mar; 31(2):295-302. PubMed ID: 28132441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
    Nakamura K; Kawamoto S; Osuga T; Morita T; Sasaki N; Morishita K; Ohta H; Takiguchi M
    J Vet Intern Med; 2017 Mar; 31(2):316-325. PubMed ID: 28145607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R-R interval variations influence the degree of mitral regurgitation in dogs with myxomatous mitral valve disease.
    Reimann MJ; Møller JE; Häggström J; Markussen B; Holen AE; Falk T; Olsen LH
    Vet J; 2014 Mar; 199(3):348-54. PubMed ID: 24507881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between syringomyelia and myxomatous mitral valve disease in Cavalier King Charles spaniels.
    Bach MBT; Stougaard CL; Thøfner MS; Reimann MJ; Westrup U; Koch J; Fredholm M; Martinussen T; Berendt M; Olsen LH
    J Vet Intern Med; 2024; 38(2):904-912. PubMed ID: 38391152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cellular changes in Cavalier King Charles spaniel and mixed breed dogs with myxomatous mitral valve disease.
    Lu CC; Liu MM; Culshaw G; French A; Corcoran B
    J Vet Cardiol; 2016 Jun; 18(2):100-9. PubMed ID: 26860643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation.
    Morgan KRS; Monteith G; Raheb S; Colpitts M; Fonfara S
    Vet J; 2020 Sep; 263():105518. PubMed ID: 32928487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma and serum serotonin concentrations and surface-bound platelet serotonin expression in Cavalier King Charles Spaniels with myxomatous mitral valve disease.
    Cremer SE; Kristensen AT; Reimann MJ; Eriksen NB; Petersen SF; Marschner CB; Tarnow I; Oyama MA; Olsen LH
    Am J Vet Res; 2015 Jun; 76(6):520-31. PubMed ID: 26000599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitral valve transcriptome analysis in thirty-four age-matched Cavalier King Charles Spaniels with or without congestive heart failure caused by myxomatous mitral valve disease.
    Reimann MJ; Cremer S; Christiansen L; Ibragimov E; Gao F; Cirera S; Fredholm M; Olsen LH; Karlskov-Mortensen P
    Mamm Genome; 2024 Mar; 35(1):77-89. PubMed ID: 37938355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine 5-hydroxyindoleacetic acid in Cavalier King Charles spaniels with preclinical myxomatous mitral valve disease.
    Christiansen LB; Cremer SE; Helander A; Madsen T; Reimann MJ; Møller JE; Höglund K; Ljungvall I; Häggström J; Olsen LH
    Vet J; 2019 Aug; 250():36-43. PubMed ID: 31383418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.